In patients with heart failure the risk of systemic thromboembolism and the benefit of anticoagulation are uncertain. To assess the incidence of systemic thromboembolism and the factors associated with an increased risk, 406 consecutive patients with chronic heart failure were prospectively investigated. Their left ventricular ejection fraction was 23 ± 8%, pulmonary wedge pressure 19±10mmHg and cardiac index 2-3 ± 1-4 1. min" m of body surface area. Two hundred patients were in NYHA functional class IH-IV. Two hundred and thirty-two patients were receiving oral anticoagulants. Over a follow-up period of 16 ± 11 months, thromboembolism occurred in 11 patients (2-7%), seven of whom were on anticoagulants. Among clinical, echocardiographic and haemodynamic variables, atrial fibrillation, more severe haemodynamic impairment and low exercise capacity were associated with increased thromboembolic risk. No echocardiographic findings, including the presence of intracavitary thrombi, either at baseline or during follow-up, were related to subsequent thromboembolic events. The rate of embolism did not differ in patients receiving anticoagulants (4%) compared with those who did not receive anticoagulants (1%). No major bleeding occurred during follow-up. Thus, in patients with chronic heart failure and sinus rhythm the incidence of systemic thromboembolism is low regardless of anticoagulant treatment. Atrial fibrillation, particularly when associated with low cardiac index, identifies a subgroup of patients at high risk of events. In this subgroup, a moderate-intensity anticoagulant regimen provides unsatisfactory protection against thromboembolism.
Introduction
Previous studies have shown that, in patients with dilated cardiomyopathy, thrombi within the left heart cavities are frequent and represent a potential source of systemic emboli [1 ' 21 . In 1981, Fuster et alP ] found that thromboembolism occurred in 32% of patients per year with dilated cardiomyopathy who were not anticoagulated while no events occurred in treated patients. Based on these results, long-term anticoagulant therapy has been recommended in such patients in order to reduce the incidence of embolic events' 4 '. More recent studies, however, led to conflicting results regarding the incidence of systemic thromboembolism, the predisposing factors and the benefit of anticoagulants' 5 " 13 ' . In addition, the haemorrhagic risk of anticoagulation in patients with congestive heart failure is expected to be increased because of hepatic congestion and interactions with other medications, but the few available data are discordant' 14 ' l5 '. In post-infarction patients, twodimensional echocardiography has proved to be a reliable tool for detecting intracardiac thrombi' 16 ' 171 , following up their evolution' 18 ', and assessing the risk of embolism' 7 ' 19 ' . In patients with dilated cardiomyopathy and heart failure, however, the contribution of echocardiography in the definition of thromboembolic risk remains uncertain' 5 ' 6 -8 -10 ' 13 '. Accordingly, this prospective study was performed to assess the incidence of systemic thromboembolism in patients with chronic heart failure and to investigate whether any clinical, haemodynamic or echocardiographic variables could identify subgroups at different risks.
Methods

Study population
The study population consisted of 406 patients with chronic heart failure, consecutively admitted to our Heart Failure Unit for pre-heart transplant evaluation from September 1992 to May 1995. All patients had had at least two episodes of congestive heart failure requiring hospitalization in the 6 months preceding the admission to our centre. The principal characteristics of the study population are summarized in the Table 1 . The mean duration of heart failure symptoms before entry into the study was 62 ± 50 months. After a run-in period, in which the therapy was adjusted in order to stabilize clinical and haemodynamic conditions, all patients underwent a complete clinical, ergometric, echocardiographic and haemodynamic evaluation. Two hundred and four (50%) patients were then admitted to the waiting list for heart transplantation. Of the remaining 202, 35 had a major contraindication and 167 were considered 'too well' to be transplanted. All patients were entered onto the heart failure data base 120 ' and were closely followed up in our centre by serial clinical, echocardiographic and haemodynamic evaluation every 6 months. No patient dropped out from the study.
Anticoagulation therapy (either warfarin or acenocumarine) was recommended in patients with a valvular prosthesis, atrial fibrillation and intracavitary thrombi detected by two-dimensional echocardiography. The decision whether a patient should be treated with anticoagulants, however, was based on the judgement of the attending cardiologist. The dose of anticoagulants was titrated to keep the prothrombin time level between 2 and 3 of the International Normalized Ratio' 4 '. At baseline evaluation 194 (48%) patients were receiving anticoagulant and the anticoagulant treatment was started in a further 50 patients during follow-up. Forty of the 174 patients who were not anticoagulated received an antiplatelet agent. In 12 patients anticoagulants were discontinued because of either poor compliance in taking therapy, minor bleeding or hepatic insufficiency.
Follow-up
The mean duration of follow-up was 16 ± 11 months. Patients who died (n=122) or were transplanted (n = 76) were removed from the analysis on the date of these events. We considered systemic thromboembolic events to be: (1) ischaemic strokes, defined as the abrupt onset of focal neurological deficits in the distribution territory of a single brain artery persisting for more than 24 h. The ischaemic nature of the cerebral lesion had to be confirmed by a CT or MRI scan. 
Echocardiographic evaluation
Standard echocardiographic studies were performed, at baseline and every 6 months, using either Sonos 1000 or 2500 Hewlett Packard systems with 2-5 and 3-5 MHz probes and recorded on Super-VHS Panasonic videotape for subsequent analysis. In all, 1142 technically adequate echocardiograms were obtained from 396 patients.
Left atrial and left ventricular diameters were measured by M-mode echocardiography according to the recommendations of the American Society of Echocardiography
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. Left ventricular volumes, and ejection apical two-and four-chamber views were made using the modified Simpson's rule. Mitral regurgitation was diagnosed and semiquantitatively graded by colour flow Doppler from the apical views' 22 '. Left-sided intracavitary thrombi were sought for systematically. The diagnosis of left ventricular and atrial thrombus was made when a well-circumscribed echogenic mass, clearly distinguishable from papillary muscles, trabeculae and Eur Heart J, Vol. 17, September 1996 endocardium was visualized in at least two views. Intracavitary echoes that did not meet all these criteria were not considered as thrombi.
incidence of systemic thromboembolism did not differ between the two groups, and no major bleeding occurred in either group during follow-up.
Statistical analysis
All descriptive data are given as mean ± 1 standard deviation. Unpaired Student's t-test and a Fisher's exact test were used to compare differences between groups of continuous and categorical variables, respectively. Stepwise regression analysis was carried out, using SAS statistical software, to determine the independent factors associated with thromboembolism [231 . Thromboembolism-free survival of different groups was assessed with Kaplan Meier curves.
Results
Arterial embolization
During a follow-up of 16±11 months, systemic thromboembolism occurred in 11 patients (2-7%): seven had a stroke (fatal in two cases), one had multiple transient ischaemic attacks, and three patients had acute limb ischaemia ( Table 2 ). The characteristics of patients grouped according to the occurrence of thromboembolism are shown in Table 3 . Between the two groups, there were no significant differences in age, functional status, aetiology of heart failure, occurrence of pulmonary embolism, history of previous systemic thromboembolism, therapy or echocardiographic findings. In contrast, patients who developed thromboembolism were more frequently in atrial fibnllation (seven of 11 vs 57 of 395, / > <0-005), had a higher level of serum bilirubin, and more compromised central haemodynamics (Table 3) . Stepwise regression analysis combining clinical, echocardiographic and haemodynamic variables, revealed that atrial fibrillation was a strong independent predictor of systemic thromboembolism. Low cardiac output (cardiac index <2-2 1 . min~' . m"
2 ) provided a small contribution of borderline statistical significance ( Table 4 ). The sensitivity of the model for predicting thromboembolic events was 91%, and the specificity 65%. The thromboembolism-free survival curves in patients subdivided according to the presence of atrial fibrillation and low cardiac index are shown in Fig. 1 . The principal characteristics of patients with and without atrial fibrillation are reported in Table 5 .
Anticoagulant therapy
Apart from atrial fibrillation and valvular aetiology, there were no differences in any considered variable between patients who were treated with anticoagulants and those who were not (Table 6 ). In addition, the
Left-sided intracavitary thrombus
A thrombus was detected by two-dimensional echocardiography in 10 patients at the first echocardiographic evaluation: nine were localized within the left ventricle and one, occurring in a patient with a mitral prosthesis, within the left atrium. In nine patients thrombi were laminated and non-protruding, while in one the thrombus was mobile and protruded into the left ventricular cavity. This was the only patient with an intracavitary thrombus who had systemic thromboembolism (limb ischaemia). Anticoagulation therapy was started in the five patients who were not treated at entry.
In five patients, two-dimensional echocardiography documented disappearance of thrombus during follow-up, while in one patient the thrombus remained unchanged. Of the remaining four patients who had a thrombus at entry, two died and two were transplanted before being re-evaluated.
Three hundred and ten patients underwent at least two echocardiographic examinations during the follow-up. De novo thrombus formation was never documented by serial echocardiograms, either in patients taking or not taking anticoagulants. Table 7 sets out the characteristics of patients with and without left-sided intracavity thrombosis.
Discussion
There is persistent uncertainty about the incidence of systemic thromboembolism, the factors associated with increased risk and the benefit of anticoagulation in patients with chronic heart failure 15 " 13) . In this prospective study, conducted on a large group of consecutive patients with severe heart failure undergoing extensive pre-heart transplant evaluation and a close follow-up, we have shown that the overall rate of systemic thromboembolism is low (2-7% after a mean follow up period of 16 months). In an attempt to identify subgroups of patients at different risk, we analysed a comprehensive set of clinical, echocardiographic and haemodynamic variables. We found that patients who developed systemic thromboembolism more frequently had atrial fibrillation, had more compromised haemodynamics and lower exercise capacity. In contrast, no echocardiographic findings including the presence of left ventricular thrombus either at baseline or during follow-up, were associated with an increased risk of systemic thromboembolism.
The incidence of systemic thromboembolism found in previous studies ranged from 0-9% to 42% per year [l3] who found a 3% incidence per year of systemic thromboembolism in 224 patients awaiting heart transplantation. Similar percentages were found in V-HeFT studies (3-2% per year) ' 12 ' and in the SOLVD study (1-7 per year) 1 " 1 which included patients with less advanced heart failure due to various cardiac diseases. In these studies, as in ours, there were patients in atrial fibrillation and anticoagulants were given according to the decision of the attending physician.
These relatively low incidences of systemic thromboembolism make the recognition of subgroups of patients at high risk, who are more likely to benefit from anticoagulation therapy, even more relevant. [27] and Segal et a/. [28] showed that in idiopathic cardiomyopathy, those with atrial fibrillation had a greater event rate compared with patients in sinus rhythm. ns ns n = number of patients; NYHA = New York Heart Association; VO 2 = 0xygen consumption.
These findings were subsequently not confirmed by other studies dealing with heart failure patients' 12 ' 131 . Since it is likely that anticoagulants were more often used in patients considered at higher risk, such as those in atrial fibrillation, this surprising finding may simply reflect the protective effect of therapy. Contrary to these studies, but in accordance with Fuster's study' 3 ', in our experience, atrial fibrillation was an important predictor of subsequent systemic thromboembolism. The event rate in patients in atrial fibrillation was 11%, and this despite the fact that 73% of them were receiving anticoagulants. Indeed, six of seven patients in atrial fibrillation who had systemic thromboembolism were taking anticoagulant therapy.
The event rate in patients who were in sinus rhythm was much lower (1%) than in patients with atrial fibrillation, and, once again, apparently not affected by anticoagulant therapy. In fact, of the four patients who had events, two were anticoagulated (1-4%) and two (1%) were not. The same apparent lack of benefit to anticoagulation has been observed by other studies 1 "" 131 . In all, however, as in ours, anticoagulant therapy was not randomized, which imposes caution in interpreting the results. Despite the fact that the attending physician most probably gave anticoagulants when he felt that patients were at higher risk, in our study, patients taking and those not taking anticoagulants were comparable for each considered variable, once those with atrial fibrillation and valvular disease were excluded. We cannot rule out, however, that the effect of 'unspoken inferences and intuitions'' 291 of the attending physician on the decision to treat may have influenced the results, making the groups different in some non-considered variables. What can be safely gathered from our results is that the protective effect of anticoagulants in patients with severe congestive heart failure is less than expected according to previous experience' 3 ' 241 . It may be possible that in our patients the moderate-intensity regimen, recommended in patients with heart failure to minimize the risk of bleeding'
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, was inadequate to prevent systemic thromboembolism. Our data confirmed that this 'prudent' regimen is safe since no major bleeding occurred and anticoagulants had to be withdrawn in only 12 patients.
The degree of left ventricular dysfunction is another factor whose predisposing role in left ventricular thrombus formation and embolization remains controversial. In accordance with recent reports' 6 ' 8 ' 12 ' 131 , we were not able to document any relationship between left ventricular dimension, ejection fraction and subsequent systemic thromboembolism. The narrow ranges of these variables in our population may explain, in part, these results. Conversely, we found that patients with more compromised haemodynamics and lower exercise capacity had a higher risk of events. This is in line with the results of V-HeFT studies' 121 which demonstrated that patients who developed thromboembolism had lower peak oxygen consumption. No correlations between events and haemodynamic impairment were found by Natterson et a/.' 131 . In Natterson's outpatients, however, cardiac outputs were higher and pulmonary wedge pressures lower than in our patients. When analysed with a multivariate technique, apart from atrial fibrillation which emerged as the strongest predictor of events, only cardiac index appeared to contribute marginally to the definition of risk, with borderline statistical significance. (7-6%) and, even more so, by Tobin et a/.' 61 (1%) in patients with congestive heart failure. Furthermore, in the latter's study, as in ours, no thrombus formation was documented by serial echocardiographic examinations.
Several reasons account for these discrepancies. Firstly, the echocardiographic diagnosis of left ventricular thrombus in patients with dilated cardiomyopathy is problematic since thrombi are generally small and difficult to distinguish from coarse trabeculations. This may easily lead either to over-or to underestimate the presence of thrombus, despite a strict standardization of diagnostic criteria. Secondly, in our study, a large number of patients were anticoagulated. By considering only the 174 patients not taking anticoagulants the frequency of left ventricular thrombus increased up to 5% which approaches the percentage reported by Natterson' 131 . Finally, mitral regurgitation, which was frequent in our patients, may exert a protective effect against thrombus formation by increasing intraventricular blood flow velocities'
Confirming the result of most of the previous studies'
5 ' 6 ' 8 ' 131 we found that, besides being rare, left ventricular thrombus was not associated with subsequent systemic thromboembolism except in one patient who had a mobile and protruding thrombus. Either the limited accuracy of two-dimensional echocardiography in detecting left ventricular thrombus or the involvement of different mechanisms responsible for thromboembolism may explain this lack of correlation. We found that the frequent association of atrial fibrillation with thromboembolism and the high prevalence of left atrial thrombus in patients with heart failure documented by Vigna et alP 2] in a transoesophageal echocardiographic study support the hypothesis that in some patients emboli may arise from the left atrium.
Study limitations
This is the first prospective study which investigates the prevalence of intracavitary thrombi and the risk of systemic embolization in a large cohort of consecutive patients with advanced chronic heart failure. However, several limitations must be acknowledged. Firstly, the administration of anticoagulant therapy was not randomized, so that we cannot establish whether anticoagulant had a protective effect against systemic thromboembolism or not. Secondly, haemostatic abnormalities which may represent important predisposing factors' 33 ' 341 , were not systematically investigated. Finally, vascular sources of thromboembolism were not routinely looked for. Nearly half of our patients had ischaemic cardiomyopathy and potentially peripheral atherosclerotic disease. Thus, due to the limited accuracy of clinical criteria for differentiating between cardiogenic and vascular embolism, it is possible that vascular sources within the aorta or the carotid arteries may have been responsible for some of the events.
Conclusions and practical implications
The present study shows that the risk of systemic thromboembolism in patients with severe heart failure in sinus rhythm is low regardless of anticoagulation treatment. Although this study was not specifically designed to assess the benefit of anticoagulation, this finding suggests that routine use of anticoagulant may not be justified and underscores the importance of identifying subgroups of patients at high risk of thromboembolism. To this purpose, transthoracic echocardiography proved of limited value since no echocardiographic findings were predictive of subsequent events and serial examinations did not improve the definition of thromboembolic risk. In contrast, atrial fibrillation, particularly when associated with a low cardiac output, identifies patients at high risk of thromboembolism who definitely need to be treated. The moderate-intensity regimen of anticoagulation we used, however, provided, if any, only sub-optimal protection against thromboembolism. This result implies that in this subgroup of patients the mechanisms of thromboembolism should be extensively investigated and new therapeutic strategies explored.
